Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

1.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.

The American journal of surgical pathology·2026
Same author

Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

Blood advances·2026
Same author

Protein <i>S</i>-acylation dynamics provide metabolic plasticity to acute myeloid leukemia cells.

bioRxiv : the preprint server for biology·2026
Same author

Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia.

Blood neoplasia·2026

Related Experiment Video

Updated: Jul 15, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.3K

Enhancing dendritic cells by inhibiting BCL2.

Christopher A G Booth1, Andrew A Lane1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Trends in Cancer
|October 2, 2023
PubMed
Summary

Inhibiting BCL2 enhances dendritic cell function, boosting T cell activation against tumors. This improves the immune system's ability to fight cancer by enhancing antigen presentation.

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Immunology

Background:

  • Dendritic cells are crucial for initiating anticancer immune responses.
  • They present tumor-associated antigens to T cells, stimulating adaptive immunity.
  • Dysfunctional antigen presentation by dendritic cells can impair antitumor responses.

Purpose of the Study:

  • To investigate the impact of BCL2 inhibition on dendritic cell function.
  • To determine if BCL2 inhibition enhances antigen presentation to T cells.
  • To assess the effect of BCL2 inhibition on T cell-mediated antitumor cytotoxicity.

Main Methods:

  • Utilized BCL2 inhibitors in preclinical models.
  • Assessed dendritic cell maturation and antigen-presenting capacity.
Keywords:
BCL2 inhibitiondendritic cellsimmunotherapy

More Related Videos

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood
07:35

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood

Published on: December 24, 2016

20.4K
Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

10.7K

Related Experiment Videos

Last Updated: Jul 15, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.3K
Generation of Human Monocyte-derived Dendritic Cells from Whole Blood
07:35

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood

Published on: December 24, 2016

20.4K
Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

10.7K
  • Measured T cell activation and proliferation in response to antigen-pulsed dendritic cells.
  • Evaluated in vivo antitumor efficacy.

    • Main Results:

    • BCL2 inhibition significantly improved dendritic cell antigen presentation.
    • Enhanced antigen presentation led to increased T cell activation and proliferation.
    • Mice treated with BCL2 inhibitors showed enhanced antitumor cytotoxicity.
    • BCL2 inhibition augmented the ability of dendritic cells to prime T cells for tumor killing.

    Conclusions:

    • Targeting BCL2 is a promising strategy to enhance dendritic cell-mediated anticancer immunity.
    • BCL2 inhibition can overcome deficits in dendritic cell function, improving T cell responses.
    • This approach holds potential for improving cancer immunotherapy outcomes.